DeliNova

DeliNova Therapeutics focuses on a "multi-dimensional" engineered viral vector modification and T-cell specific delivery platform. By precisely modifying lentiviral vectors, the company directly, efficiently, and specifically transduces T cells in vivo to generate CAR-T cells. The company’s lead pipeline, based on clinically validated targets, is expected to soon initiate investigator-initiated trials (IIT) for hematological tumors, while also entering the IND preparation phase. The IIT for autoimmune diseases and solid tumors is planned to commence in 2026. In the future, DeliNova Therapeutics will further expand its range of targeted platform technologies for various immune cells, exploring application potential in chronic disease fields such as anti-aging.